Neurogene Inc., a clinical stage biotechnology company, develops genetic medicines for rare neurological diseases. The company's product candidates include NGN-401 that is packaged in an adeno-associated virus 9, which is in Phase 1/2 clinical trial for the treatment of Rett syndrome; and NGN-101, a conventional gene therapy candidate that is in Phase 1/2 clinical trial to treat CLN5 Batten disease. It has a license agreements with The University of Edinburgh, Virovek, Inc., Sigma-Aldrich Co. LLC., and Leland Stanford Junior University. The company was founded in 2018 and is headquartered in New York, New York. Show more
Location: 535 W 24th Street, New York, NY, 10011, United States | Website: https://www.neurogene.com | Industry: Biotechnology | Sector: Healthcare
Market Cap
230.5M
52 Wk Range
$6.88 - $74.49
Previous Close
$16.16
Open
$16.33
Volume
205,426
Day Range
$14.93 - $16.33
Enterprise Value
-50.42M
Cash
292.6M
Avg Qtr Burn
-17.43M
Insider Ownership
9.28%
Institutional Own.
-
Qtr Updated
03/31/25
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Phase 1/2 Data readout | ||
NGN-101 Details Rare genetic disease, Batten Disease | Failed Discontinued |